What is claimed is:

1. A compound of the formula I



I

wherein

A^1 is a 5-9 membered monocyclic or 7-12 membered polycyclic heterocycle of the formula



containing at least one nitrogen atom and 0 to 5 heteroatoms or groups selected from O, N, S, SO_2 or CO; optionally saturated or unsaturated; optionally substituted by one or more R^k selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxy-alkyl, thioalkyl, haloalkyl, cyano, amino, alkylamino, halogen, acylamino, sulfonamide and -COR wherein R is hydroxy, alkoxy, alkyl or amino;

or A^1 is



wherein Y^1 is selected from the group consisting of N-R^2, O, and S;

R^2 is selected from the group consisting of H; alkyl; aryl; hydroxy; alkoxy; cyano; alkenyl; alkynyl; amido; alkylcarbonyl; arylcarbonyl; alkoxycarbonyl; aryloxycarbonyl; haloalkylcarbonyl; haloalkoxy-carbonyl; alkylthiocarbonyl; arylthiocarbonyl; acyloxymethoxy-carbonyl;

R^2 taken together with R^7 forms a 4-12 membered dinitrogen containing heterocycle optionally substituted with one or more substituent selected from the group consisting of lower alkyl, thioalkyl, alkylamino, hydroxy, keto, alkoxy, halo, phenyl, amino, carboxyl or carboxyl ester, and fused phenyl;

or R^2 taken together with R^7 forms a 4-12 membered heterocycle containing one or more heteroatom selected from O, N and S optionally unsaturated;

or R^2 taken together with R^7 forms a 5 membered heteroaromatic ring fused with a aryl or heteroaryl ring;

R^7 (when not taken together with R^2) and R^8 are independently selected from the group consisting of H; alkyl; alkenyl; alkynyl; aralkyl; amino; alkylamino; hydroxy; alkoxy; arylamino; amido, alkylcarbonyl, arylcarbonyl; alkoxycarbonyl; aryloxy; aryloxycarbonyl; haloalkylcarbonyl; haloalkoxycarbonyl; alkylthiocarbonyl; arylthiocarbonyl; acyloxymethoxycarbonyl; cycloalkyl; bicycloalkyl; aryl; acyl; benzoyl;

or NR^7 and R^8 taken together form a 4-12 membered mononitrogen containing monocyclic or bicyclic ring optionally substituted with one or more substituent selected from lower alkyl, carboxyl derivatives, aryl or hydroxy and wherein said ring contains 0-1 heteroatom, selected from the group consisting of O, N and S;

R^5 is selected from the group consisting of H, and alkyl;

or



A is

wherein Y^2 is selected from the group consisting of alkyl; cycloalkyl; bicycloalkyl; aryl; monocyclic heterocycles;

Z_1 is selected from the group consisting of CH_2, O, CH_2O, NH, CO, S, SO, CH(OH) and SO_2;

Z_2 is a 1-5 carbon linker optionally containing one or more heteroatom selected from the group consisting of O, S and N; alternatively Z_1 - Z_2 may further contain a carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, or acyl group; wherein the carbon and nitrogen atoms of Z_1 - Z_2 are optionally substituted by alkyl, alkoxy, thioalkyl, alkylsulfone, aryl, alkoxyalkyl, alkylamino, heteroaryl, hydroxy, alkenyl, alkynyl, carboxyalkyl, halogen, haloalky or acylamino;

is an integer 0, 1 or 2;

R^c is selected from the group consisting of hydrogen; alkyl; halogen, hydroxy, nitro, alkoxy, amino, haloalkyl, aryl, heteroaryl, alkoxyalkyl, aminoalkyl, hydroxyalkyl, thioalkyl, alkylamino, arylamino, alkylsulfonylamino, acyl, acylamino, sulfonyl, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, alkynylalkyl, carboxy, alkoxycarbonyl, carboxamido, cyano, and $-(CH_2)_n$-COR wherein n is 0-2 and R is selected from hydroxy, alkoxy, alkyl and amino;

X is selected from the group consisting of -O-, CO, SO_2, NR^m and $(CHR^p)_n$; wherein R^p and R^m are H or alkyl, n is 0-2;

R^b is X_3 - R^h wherein X_3 is selected from the group consisting of O, S and NR^j wherein R^h and R^j are independently selected from the group consisting of H, alkyl, acyl, aryl, aralkyl and alkoxyalkyl; and

The ring A-B , 

is selected from the group consisting of



all optionally substituted and bonded to X and Z_1 at any position;

and pharmaceutically acceptable salts, isomers, enantiomers, tautomers, racemates and polymorphs thereof.

2. A compound according to Claim 1 wherein  is selected from the group consisting of


B2


B3

and


B4

wherein Z_a is H, alkyl, alkoxy, hydroxy, amine, alkylamine, dialkylamine, carboxyl, alkoxycarbonyl, hydroxyalkyl, halogen or haloalkyl and R^1 is H, alkyl, alkoxyalkyl, acyl, haloalkyl or alkoxycarbonyl, and pharmaceutically acceptable salts, isomers, enantiomers, tautomers, racemates and polymorphs thereof.

3. A compound according to claim 1 wherein  is selected from the group consisting of



wherein X_4 and X_5 are selected from the group consisting of H, alkyl, branched alkyl, alkylamino, alkoxyalkylamino, haloalkyl, thioalkyl, halogen, amino, alkoxy, aryloxy, alkoxyalkyl, hydroxy, cyano, acylaminomethyl, methoxy, amine, methylamine, trifluoromethyl, dimethyl-amine, hydroxy, chloro, bromo, fluoro and cyano; X_6 is H, alkyl, hydroxy, halogen, alkoxy and haloalkyl; the pyridyl ring can be fused with a 4 - 8 membered ring, optionally saturated or unsaturated, and pharmaceutically acceptable salts, isomers, enantiomers, tautomers, racemates and polymorphs thereof.

4. A compound according to claim 1 wherein when Z_1 is CO or SO_2, and the linkage A^1-Z_2 is a heterocycle derived ring system selected from the group consisting of pyridine, imidazole, thiazole, oxazole, benzimidazole, and imidazopyridine, and pharmaceutically

acceptable salts, isomers, enantiomers, tautomers, racemates and polymorphs thereof.

5. A compound according to claim 4 wherein the heterocycle derived ring systems for A^1-Z_2 are selected from the group consisting of:



B = NH, O, S
R = H, Me



B = NH, O, S
R = H, Me



B = NH, O, S
R = H, Me



B = NH, O, S
R = H, Me



B = NH, O, S
R = H, Me



B = N, CH
R = H, Me



B = N, CH
R = H, Me



B = NH, O, S
R = H, Me



B = N, CH
R = H, Me

and pharmaceutically acceptable salts, isomers, enantiomers, tautomers, racemates and polymorphs thereof.

6. A compound according to Claim 1 wherein the ring A-B



is a tetrahydronaphthalene



and Z_1 is S, and pharmaceutically acceptable salts, isomers, enantiomers, tautomers, racemates and polymorphs thereof.

7. A compound according to claim 1, wherein the ring A-B



is a tetrahydronaphthalene



;

Z_1 is a CH_2;

A^1 is selected from the group consisting of:



B = CH_2, O, CO, S, CF_2, SO_2, NR
R' = OR, OH, H, Me n = 1 or 2



B = NH, O, S



B = N, CH



B = NH, O, S



B = NH, O, S



B = N, CH
R = H, Me











X = O, S, NR, SO_2, CF_2



X = CH_2, O, S, NR, SO_2, CONR



B = CH_2, O, CO, S, CF_2, SO_2, NR
R' = OR, OH, Me

and pharmaceutically acceptable salts, isomers, enantiomers, tautomers, racemates and polymorphs thereof.

8. A compound according to claim 1, wherein

the ring A-B  is 

A^1 is selected from the group consisting of :



and pharmaceutically acceptable salts, isomers, enantiomers, tautomers, racemates and polymorphs thereof.

9. A compound according to claim 1 selected from the group consisting of:

[2,2-dimethyl-3-oxo-8-[3-(pyridin-2-ylamino)propoxy]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]acetic acid;

1,2,3,4-tetrahydro-6-[3-(2-pyridinylamino)propoxy-2-isoquinoline-propanoic acid;

{5-[3-(pyridin-2-ylamino)propoxy]-1H-indol-1-yl}acetic acid;

2,3-dihydro-5-[3-(2-pyridinylamino)propoxy]-1H-indene-2-acetic acid;

2, 3, 4, 5-tetrahydro-5-oxo-8-[3-(2-pyridinylamino)propoxy]-1,4-benz-oxazepine-4-acetic acid;

2,3,4,5-tetrahydro-8-[3-(2-pyridinylamino)propoxy]1,4-benzoazepine-4-acetic acid;

1,2,3,4-tetrahydro-1-oxo-6-[3-(2-tetrahydropyrimidinyl)amino]-propoxy]-2-isoquinolineacetic acid;

3,4-dihydro-7-[3-(2-pyridinylamino)propoxy]-2-H-1-benzopyran-3-acetic acid;

(6-{[3-(pyridin-2-ylamino)propyl]thio}-1,2,3,4-tetrahydronaphthalen-2-yl)acetic acid;

1,2,3,4-tetrahydro-6-[2-(5,6,7,8-tetrahydro-1,8-naphthyridyl)-amino-ethyloxy]2-naphthaleneacetic acid, and pharmaceutically acceptable salts, isomers, enantiomers, tautomers, racemates and polymorphs thereof.

10. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claims 1-9 and a pharmaceutically acceptable carrier.

11. A method for treating conditions mediated by the $\alpha_V\beta_3$ integrin in a mammal in need of such treatment comprising administering an effective $\alpha_V\beta_3$ inhibiting amount of a compound of Claims 1-9.

12. The method according to Claim 11 wherein the condition treated is selected from the group consisting of tumor metastasis, tumor growth, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atheroscelorosis, macular degeneration, retinopathy, and arthritis.

13. A method for treating conditions mediated by the $\alpha_V\beta_5$ integrin in a mammal in need of such treatment comprising administering an effective $\alpha_V\beta_5$ inhibiting amount of a compound of Claims 1-9.

14. The method according to Claim 13 wherein the condition treated is selected from the group consisting of tumor metastasis, tumor growth, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atheroscelorosis, macular degeneration, retinopathy, and arthritis.

15. A method of treating neoplasia in a patient in need thereof comprising administering a compound of Claims 1-9 in combination with a chemotherapeutic agent.

16. A compound of Claims 1-9 that selectively antagonizes the $\alpha_V\beta_3$ and the $\alpha_V\beta_5$ integrins, over the $\alpha_V\beta_6$ integrin.